Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00177827
• Date of registration: 13/09/2005
• Primary sponsor: University of Pittsburgh
• Public title: Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients
• Scientific title: Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients: Pharmacokinetics and Correlation Between Plasma and Lung Concentrations With Toxicity/Efficacy
• Date of first enrolment: March 2004
• Target sample size: 104
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00177827
• Study type: Observational
• Study design: Observational Model: Case-Only, Time Perspective: Prospective

Countries of recruitment

United States

Contacts

• Name: Blair Capitano, Pharm D
• Affiliation: University of Pittsburgh

Key inclusion & exclusion criteria

Inclusion Criteria:

- Male or female lung transplant recipients, greater than 18 years old, who are
initiated on the voriconazole prophylactic regimen (Figure 1) by their transplant
physician as standard care will be eligible for inclusion in the study.

Exclusion Criteria:

- Patients receiving voriconazole to treat an active fungal infection will be excluded.
Patients that are concurrently receiving medications that are documented to affect
voriconazole pharmacokinetics will be excluded. The agents included, but may not be
limited to the following ;carbamazepine, phenytoin, omeprazole, rifabutin and
rifampin.10



Age minimum: 18 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Post Lung Transplantation

Secondary ID(s)

IRB# 0304017

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Center for Research Resources (NCRR)